Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.50 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TGM1 | P22735 | 1/20 | 0.50 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11179193 | 0.74 | TGM2 (0.53) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL5553620 | 0.71 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL5480363 | 0.71 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL31043510 | 0.70 | TGM2 (0.42) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL26026744 | 0.70 | TGM2 (0.48) | TGM2F13A1LMNATGM1TGM3 | |
| Acrylamide SCHEMBL28343508 | 0.69 | TGM2 (0.47) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL2723006 | 0.68 | TGM2 (0.42) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL5495518 | 0.67 | TGM2 (0.50) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL28741410 | 0.67 | TGM2 (0.55) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL9865216 | 0.67 | TGM2 (0.68) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032398-A1 | HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20190382519-A1 | CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2019-12-19 | — | — | US | disclosed |
| WO-2018132548-A1 | CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2018-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382519-A1 | CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF | ADSL, ABHD6, APH1B | TGM2 1972/4885F13A1 1204/4885LMNA 2576/4885 |
| US-20250032398-A1 | HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF | PCNA, ADSL, APH1B | TGM2 2386/4885F13A1 983/4885LMNA 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.